Identification of clinically actionable secondary genetic variants from whole-genome sequencing in a large-scale Chinese population

Clin Transl Med. 2022 May;12(5):e866. doi: 10.1002/ctm2.866.

Pei-Kuan Cong^{1

2

3}, Saber Khederzadeh^{1

2

3}, Cheng-Da Yuan⁴, Rui-Jie Ma¹, Yi-Yao Zhang¹, Jun-Quan Liu⁵, Shi-Hui Yu⁵, Lin Xu⁶, Jian-Hua Gao⁷, Hong-Xu Pan^{8

9}, Jin-Chen Li^{8

9}, Shu-Yang Xie⁶, Ke-Qi Liu⁷, Bei-Sha Tang^{8

9}, Hou-Feng Zheng^{1

2

3}

¹ Diseases & Population (DaP) Geninfo Lab, School of Life Sciences, Westlake University, Hangzhou, Zhejiang, China.
² Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang, China.
³ Institute of Basic Medical Sciences, Westlake Institute for Advanced Study, Hangzhou, Zhejiang, China.
⁴ Department of Dermatology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
⁵ Clinical Genome Center, KingMed Diagnostics, Co. Ltd., Guangzhou, Guangdong, China.
⁶ WBBC Shandong Center, Binzhou Medical University, Yantai, Shandong, China.
⁷ WBBC Jiangxi Center, Jiangxi Medical College, Shangrao, Jiangxi, China.
⁸ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
⁹ Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan, China.

No abstract available

Publication types